Breast Cancer Disease Burden in Albania
AJTES Vol 6, No 2, July 2022
Pema E et al - Breast Cancer Disease Burden in Albania.


breast cancer
Oncology Service
pathological profile

How to Cite

Pema (Kristo), A., Tarifa, D., Ikonomi, M., Proko, F., Ymeri, A., Shehu, L., & Poga, B. (2022). Breast Cancer Disease Burden in Albania. Albanian Journal of Trauma and Emergency Surgery, 6(2), 1043-1047.


Introduction; There are data on an increase in cancer cases in Albania in recent decades, this growing trend of cancer in the Albanian population is due to the rapid increase of habits or unhealthy behaviours such as; smoking, excessive alcohol consumption, unhealthy diet, high levels of obesity, and physical inactivity. However, Albanian men and women show one of the lowest values (in terms of age) in the region of Southeast Europe. In Albania still, we do not have official data regarding the number of breast cancer diagnosed patients either their characteristics, or pathological profile.

Our purpose is to conduct retrospective study of number of Breast Cancer patients treated and diagnosed in Albania during 2018.     

Material and Methods; We have recorded and recorded all breast cancer data from the registry of the Oncology Service at University Hospital Center “Mother Teresa “and private clinics in Tirana and from the registries of the district hospitals, during 2018.

Results; Total number of breast cancer patients treated and diagnosed in 2018, from them 506 patients were diagnosed and treated with breast cancer of all stages in our hospital. Since the registry of cancer is still not untirely functioning the data represents only our hospital not.

Conclusions; Breast cancer remains a major public health concern worldwide. Trends in the incidence, mortality, and regulated life years of the disabled are varied across regions and countries, suggesting the allocation of appropriate health care resources for breast cancer, which should have the highest level of evaluation.
Pema E et al - Breast Cancer Disease Burden in Albania.


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492 PubMed Abstract | CrossRef Full Text | Google Scholar

Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8(6):697–702. [PubMed] [Google Scholar]

Ferley J, SoerjomataramI I, Ervik M, Dikshit R, Eser S. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [Google Scholar]

Zendehdel M, Niakan B, Keshtkar A, Rafiei E, Salamat F. Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. Iran J Med Sci. 2018;43(1):1–8. [PMC free article] [PubMed] [Google Scholar]

Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al.ABREAST Investigators The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6(5):391–401. [PubMed] [Google Scholar]

Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(s1):S70–S80. [PubMed] [Google Scholar]

Mavaddat N, Pharoah PD, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. JNCI: J Natl Cancer Inst. 2015;107(5):djv036. [PMC free article] [PubMed] [Google Scholar]

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D; Global cancer statistics; CA Cancer J Clin 61: 69–90, 2011.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009 Jul-Aug;59(4):225-249.

Zardavas D, Irrthum A, Swanton C, Piccart M. Clincal Management of breast cancer heterogeneity, Nat Rev Clin Oncol 2015;12(7):381-394

Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Database. Seattle, WA: IHME, University of Washington; 2014. (Accessed: November 12, 2017).

Stewart WB, Wild CP. Vol. 5. Lyon: World Health Organization; 2014. Breast Cancer. World Cancer Report 2014; p. 362. [Google Scholar] [Ref list]

Shaik AB, Venkataramanaiah M, Thasleema SC. Statistical applications of survival data analysis for breast cancer data. i-managers J Math. 2015;4:30–6. [Google Scholar]

Abdollahi M, Hajizadeh E, Baghestani AR, et al. Determination of a change point in the age at diagnosis of breast cancer using a survival model. Asian Pac J Cancer Prev. 2016; 17:5–10. [PubMed] [Google Scholar]

Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011, 9 (1): 48-57. 10.1038/nrclinonc.2011.178.PubMed Central Article PubMed Google Scholar

Laurinavicius, A., Laurinaviciene, A., Ostapenko, V. et al. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 7, 27 (2012).

A. Fourati, H. Boussen, M.V. El May, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer, Asia Pac J Clin Oncol, 10 (2) (2014), pp. e69-74

M. Kadivar, N. Mafi, A. Joulaee, A. Shamshiri, N. Hosseini Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011 Asian Pac. J. Cancer Prev. APJCP, 13 (5) (2012), pp. 1881-1886

L. Wiechmann, M. Sampson, M. Stempel, et al. Presenting features of breast cancer differ by molecular subtype Ann. Surg. Oncol., 16 (10) (2009), pp. 2705-2710

I. Mehdi, A.a. Abdulmasood, B.J.A. Bahrani Breast cancer molecular subtypes in Omani patients: correlation with age, histology, stage distribution, and outcome—an anaylsis of 542 cases J. Clin. Oncol., 29 (27_suppl) (2011) 219-219

D.C. Zaha, E. Lazar, C. Lazureanu Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer Rom. J. Morphol. Embryol., 51 (1) (2010), pp. 85-89

Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428–1435. doi: 10.1016/S0140-6736(11)61178-1. [PubMed] [CrossRef] [Google Scholar] [Ref list]

Bahrami A., Truong L.D., Ro J.Y. Undifferentiated tumor: True identity by immunohistochemistry. Arch. Pathol. Lab. Med. 2008;132:326–348. [PubMed] [Google Scholar] [Ref list]

Yoshida A, Hayashi N, Suzuki K, et al. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer. J Surg Oncol. 2017;116:1021–1028. doi: 10.1002/jso.24762. [PubMed] [CrossRef] [Google Scholar] [Ref list]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.